ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1269

Effective Treatment of TNFα Inhibitors in Chinese Patients with Blau Syndrome

Jing Chen 1, Yi Luo 1, Mengzhu Zhao 1, Di Wu 1, Yunjiao Yang 2, Wen Zhang 3 and Min Shen1, 1Peking Union Medical College Hospital, Beijing, Beijing, China (People's Republic), 2Peking Union Medical College Hospital, Beijing, China (People's Republic), 3Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China (People's Republic)

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: anti-TNF therapy and infliximab, Blau syndrome

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 11, 2019

Title: Miscellaneous Rheumatic & Inflammatory Disease Poster II: Autoinflammation Related Diseases & Therapies

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Blau syndrome (BS) is a rare dominantly inherited autoinflammatory disorder associated with mutations in the NOD2 gene. BS is mainly seen in Caucasian patients. Biologic therapy of BS yielded diversity results. We aimed to evaluate clinical features and outcomes of Chinese patients with BS who were treated with TNFα inhibitors.

Methods: A total of four patients with BS were diagnosed and treated with infliximab (IFX) at Peking Union Medical College Hospital during 2015 to 2018, and were followed up for 18 months. All patients were systematically studied for treatment outcomes including the clinical manifestations and inflammatory markers. We also conducted a comprehensive literature review about TNFα inhibitors therapy in BS.

Results: These four BS patients were all Chinese Han, and three of them were women. The mean age of disease onset was 4±3.5 years, and the mean time of diagnosis delay was 19±11 years. All of the 4 patients received IFX plus methotrexate, and had achieved clinical remission of skin lesions and polyarthritis rapidly, and normalization of ESR and CRP, improvements in inflammatory cytokines, patient visual analogue scale, physician global assessment and SF-36 as well, at the first follow-up of 6 months. The disease relapsed in two patients after they lengthened the interval of IFX due to the financial limitation and discontinued methotrexate because of the side effects. According to the 38 English-language publications, 62 patients with BS were presented who underwent TNFα inhibitors therapy, including IFX used in 31, adalimumab in 24 and etanercept in 7. IFX was well tolerated in 27 patients, while 2 still had uveitis, and the other 2 experienced an adverse drug reaction to IFX infusion. Adalimumab was useful in 21 BS patients, although the other 3 didn’t get well controlled. Five BS patients who were given etanercept yielded good responses, but 2 discontinued because of etanercept-induced myelopathy or an exacerbation of arthritis.

Conclusion: Early recognition and effective treatment of BS is very important to avoid the irreversible organ damage such as loss of vision, joint deformities. TNFα inhibitors including IFX may be a promising approach for BS patients who have unsatisfactory response to corticosteroids and traditional DMARDs. Due to the sample limitation of our study, more clinical trials are required.


Table 1 Demographic and clinical features of four Chinese patients with BS

Table 1 Demographic and clinical features of four Chinese patients with BS

Figure 1 Pedigrees and phenotypes of Chinese patients with BS.
Camptodactyly of patients 1 -A- and 2 -B-; Papules on the upper limbs of patient 2 -C-; Pedigrees of patients 1 and 2 -D-, 3 -E- and 4 -F-.

Figure 2 Changes in disease activity and inflammatory markers of patients.
Overall, WBC, CRP, ESR, IL-1β, IL-6, VAS and PGA decreased, and SF-36 increased at the first follow-up of 6-month. TNFα decreased at the first follow-up for patients 2 and 3, but increased for patients 1 and 4. At the last visit of 18-month, WBC, ESR and CRP remained normal in all except patient 3, whose ESR and CRP increased to above normal range. Among all the patients, serum levels of IL-1β, TNFα and IL-6 were higher than those at the first follow-up, except patient 4. For patients 1 and 2, VAS and PGA reduced further at the last follow-up, while for patients 3 and 4, they slightly increased. CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; VAS: visual analogue scale; PGA: physician global assessment; SF-36: Short Form-36.


Disclosure: J. Chen, None; Y. Luo, None; M. Zhao, None; D. Wu, None; Y. Yang, None; W. Zhang, None; M. Shen, None.

To cite this abstract in AMA style:

Chen J, Luo Y, Zhao M, Wu D, Yang Y, Zhang W, Shen M. Effective Treatment of TNFα Inhibitors in Chinese Patients with Blau Syndrome [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/effective-treatment-of-tnf%ce%b1-inhibitors-in-chinese-patients-with-blau-syndrome/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/effective-treatment-of-tnf%ce%b1-inhibitors-in-chinese-patients-with-blau-syndrome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology